View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Grey and Clear Junction Partner to Improve Global Payments for Locatio...

Grey Grey and Clear Junction Partner to Improve Global Payments for Location-Independent Individuals 27-Jan-2025 / 13:40 CET/CEST The issuer is solely responsible for the content of this announcement. Grey and Clear Junction join forces to offer faster, more efficient, cost-effective payment solutions globally for digital nomads Grey (), one of the startups in Y-Combinator’s Winter 2022 batch, is at the forefront of providing secure and convenient global banking solutions to meet the needs of customers in emerging markets. Grey’s primary focus is emerging markets, and the company...

 PRESS RELEASE

Mawson Infrastructure Group Releases Updated Company Presentation – 13...

Mawson Infrastructure Group Releases Updated Company Presentation – 136% Y/Y Revenue Growth in Digital Colocation Business, 36% Y/Y Revenue Growth in Total Revenue, and 31% Y/Y Operating Hash Rate Growth MIDLAND, Pa., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Mawson Infrastructure Group Inc. (NASDAQ: MIGI) ("Mawson" or "the Company"), a publicly-traded technology company focused on digital infrastructure platforms for artificial intelligence (AI), high-performance computing (HPC), and digital assets, today released its updated Company Presentation, which is now available on the Company's website ...

City of Chicago, IL: Update to credit analysis

Our credit view incorporating a massive economic base and revenue raising flexibility that it has tapped to improve pension contributions. The city continues to have budgetary challenges.

 PRESS RELEASE

Leslie’s, Inc. to Report First Quarter Fiscal 2025 Financial Results o...

Leslie’s, Inc. to Report First Quarter Fiscal 2025 Financial Results on February 6, 2025 PHOENIX, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Leslie’s, Inc. (NASDAQ: LESL), the largest and most trusted direct-to-consumer brand in the U.S. pool and spa care industry serving residential customers and pool professionals nationwide, today announced that its financial results for the first quarter of fiscal 2025 will be released after market close on Thursday, February 6, 2025. The Company will host a conference call at 4:30 p.m. Eastern Time to discuss the financial results. Investors and analysts i...

 PRESS RELEASE

Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) ...

Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio NEW YORK, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, announced today it was issued a new U.S. Patent N...

 PRESS RELEASE

Organogenesis Holdings Inc. to Report Fourth Quarter of Fiscal Year 20...

Organogenesis Holdings Inc. to Report Fourth Quarter of Fiscal Year 2024 Financial Results on February 27, 2025 CANTON, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical and Sports Medicine markets, today announced that fourth quarter and fiscal year 2024 financial results will be reported after the market closes on Thursday, February 27th. Management will host a conference call at 5:00 p.m....

 PRESS RELEASE

SECO and Nayax Announce Plans for Strategic Partnership to Offer IoT-I...

SECO and Nayax Announce Plans for Strategic Partnership to Offer IoT-Integrated Payment Solutions for OEMs HERZLIYA, Israel and AREZZO, Italy, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Nayax Ltd. (Nasdaq: NYAX; TASE: NYAX), a global commerce enablement and  designed to help merchants scale their business by simplifying payments and maximizing , and SECO S.p.A. (IOT.MI), a leading provider of end-to-end technological solutions for industrial digitalization, today announced the execution of a Memorandum of Understanding, (“MOU”), with the intention to establish a long-term strategic partnership to ...

Synagistics Ltd: 1 director

A director at Synagistics Ltd sold 14,287,411 shares at 0.000HKD and the significance rating of the trade was 73/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...

Moody's Ratings assigns first-time Ba3 ratings to OVH; outlook stable

Moody's Ratings (Moody's) has assigned a Ba3 long-term Corporate Family Rating (CFR) and a Ba3-PD Probability of Default Rating (PDR) to OVH Groupe S.A. (OVH or the company). Concurrently, we have assigned a Ba3 rating to the recently proposed €470 million senior unsecured notes due 2031, to be issu...

 PRESS RELEASE

Discovery Announces Transformational Acquisition of Newmont’s Porcupin...

Discovery Announces Transformational Acquisition of Newmont’s Porcupine Complex THE BASE SHELF PROSPECTUS IS ACCESSIBLE, AND THE SHELF PROSPECTUS SUPPLEMENT FOR THE PUBLIC OFFERING AND ANY AMENDMENT TO THE DOCUMENTS WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, THROUGH SEDAR+ NOT FOR DISTRIBUTION TO U.S. NEWS WIRE SERVICES OR DISSEMINATION IN THE UNITED STATES Establishes Discovery as a growing Canadian gold producer with large Mineral Resource base in a Tier 1 jurisdiction with significant upside potential Attractive acquisition with base case NPV of $1.2 billion using analyst consensus g...

 PRESS RELEASE

Issue of Equity

M&G Credit Income Investment Trust plc (MGCI) Issue of Equity 27-Jan-2025 / 12:03 GMT/BST 27 January 2025 LEI: 549300E9W63X1E5A3N24   M&G Credit Income Investment Trust plc   Issue of Equity   M&G Credit Income Investment Trust plc (the “Company”) announces that, on 27 January 2025, it issued 1,000,000 ordinary shares of one penny each (the “Ordinary Shares”) under its block listing for cash at a price of 96.60 pence per Ordinary Share to meet ongoing demand for the Company’s existing Ordinary Shares.  The new Ordinary Shares will be credited as fully paid and rank pari pass...

 PRESS RELEASE

First commercial launch of biometric payment cards in Japan with LIFE ...

First commercial launch of biometric payment cards in Japan with LIFE CARD and IDEX Biometrics Oslo, Norway and Tokyo, Japan - 27 January 2025 – IDEX Biometrics enters a new market, together with LIFE CARD, Japan’s most innovative credit card issuer. This marks the market introduction of biometric payment cards in Japan. LIFE CARD is targeting commercial deployment in the first half of 2025. Japan is one of the largest payment markets in Asia, with a very advanced acceptance landscape which is ready for biometric smart cards. Credit cards have emerged to become the most popular alternativ...

 PRESS RELEASE

Form 8.3 - [ International Paper Company]

Form 8.3 - [ International Paper Company] FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION (a)   Full name of discloser:Danske Bank A/S(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c)   Name of offeror/offeree in relation to whose relevant securities th...

Yusei Holdings: 2 directors

Two Directors at Yusei Holdings bought 18,000,000 shares at 0.510HKD. The significance rating of the trade was 92/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...

 PRESS RELEASE

Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to ...

Invivyd Provides Another Positive SARS-CoV-2 Variant Data Analysis to Satisfy U.S. FDA’s Gating Request for Completing Its Review of EUA Request for PEMGARDA™ (pemivibart) for the Treatment of Mild-to-Moderate COVID-19 in Certain Immunocompromised Patients Treatment immunobridging analysis, routinely updated for contemporary SARS-CoV-2 variants, compares pemivibart antiviral titers to adintrevimab antiviral titers from the company’s previous Phase 2/3 clinical trial of adintrevimab for the treatment of COVID-19 (STAMP), in which adintrevimab conferred a 66% to 74% reduction in risk of hospi...

 PRESS RELEASE

PyroGenesis Signs $2.5 Million Contract with Global Environmental Serv...

PyroGenesis Signs $2.5 Million Contract with Global Environmental Services Company First payment of $400,000 received MONTREAL, Jan. 27, 2025 (GLOBE NEWSWIRE) -- PyroGenesis Inc. (“PyroGenesis”) () (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY), a high-tech company that designs, develops, manufactures and commercializes advanced plasma processes and sustainable solutions which are geared to reduce greenhouse gases (GHG) and address environmental pollutants, announces that its subsidiary, Pyro Green-Gas Inc. (“Pyro Green-Gas”), has signed a contract totaling US$1.74 million (approx. CA$2.5 million)...

 PRESS RELEASE

Allakos Announces Topline Results from its Phase 1 Trial of AK006 in P...

Allakos Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic Spontaneous Urticaria and Announces Restructuring – AK006 did not demonstrate therapeutic activity in CSU –– Allakos will discontinue further development of AK006, reduce workforce by 75% and explore strategic alternatives –– Management to host conference call and webcast today at 8:30 am E.T. – SAN CARLOS, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (Company) (Nasdaq: ALLK), today announced topline results from its phase 1 clinical trial of AK006 in chronic spontaneous urticaria (CSU)...

 PRESS RELEASE

Cartesian Therapeutics Announces FDA Special Protocol Assessment Agree...

Cartesian Therapeutics Announces FDA Special Protocol Assessment Agreement for Phase 3 AURORA Trial of Descartes-08 in Myasthenia Gravis Trial on track to commence in 1H25 FREDERICK, Md., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that it has received written agreement from the U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process on the overall design of the Company’s planned Phase 3 AURORA...

 PRESS RELEASE

Gadfin Ltd. and Israel Acquisitions Corp. Announce Entry into Definiti...

Gadfin Ltd. and Israel Acquisitions Corp. Announce Entry into Definitive Business Combination Agreement, Bringing the Unmanned Aerial Delivery Company to Nasdaq TEL-AVIV, Israel, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Israel Acquisitions Corp. (NASDAQ: ISRL, ISRLU, ISRLW), (“ISRL”), a publicly-traded special purpose acquisition company, and Gadfin Ltd. (“Gadfin”), an Israeli technology company specializing in all-weather, long range, heavy-duty, drone delivery for essential cargo, today announced the entry into a definitive business combination agreement reflecting a total equity value of Gadf...

 PRESS RELEASE

Tourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotec...

Tourmaline Bio to Present at the Guggenheim Securities SMID Cap Biotech Conference NEW YORK, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced that Sandeep Kulkarni, MD, Co-Founder and Chief Executive Officer, is expected to participate in the following investor conference: Guggenheim Securities SMID Cap Biotech Conference, New YorkFireside ChatWednesday, Februa...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch